1. Artiko, V., Obradović, V., Davidović, B., Petrović, N., Petrović, M., Krivokapić, Z., Kecmanović, D., Peško, P., Djukić, V., Milosavljević, T., Adanja, G., and Vlajković, M. 2003. Radioimmunodetection of colorectal carcinoma. Hepatogastroenterology
50: 1029–1031.
2. Bares, R., Fass, J., Weiller, G., Wolter, S., Kleinhans, S., Truong, S., Bull, U., and Schumpelick, V. 1989. Clinical significance of immunoscintigraphy for the diagnosis and treatment of gastrointestinal malignant tumors. Onkologie
12: 13–18.
3. Baum, R.P., Lorenz, M., Hottenrott, C., Albrecht, M., Senekowitsch, R., Happ, J., Hertel, A., Spitz, J., and Hor, G. 1988. Radioimmunoscintigraphy using monoclonal antibodies to CEA, CA 19–9, and CA 125. Int. J. Biol. Markers
3: 177–184.
4. Behr, T.M., Goldenberg, D.M., Scheele, J.R., Wolf, F.G., and Becker, W. 1997. Clinical relevance of immunoscintigraphy with 99 mTc-labelled anti-CEA antigen-binding fragments in the follow-up of patients with colorectal carcinoma. Assessment of surgical resectability with a combination of conventional imaging methods. Dtsch. Med. Wochenschr. 122: 463–470.
5. Bischof-Delaloye, A., Delaloye, B., Buchegger, F., Gilgien, W., Studer, A., Curchod, S., Givel, J.C., Mosimann, F., Pettavel, J., and Mach, J.P. 1989. Clinical value of immunoscintigraphy in color-ectal carcinoma patients: a prospective study. J. Nucl. Med. 30: 1646–1656.